Figure summarizing the immunological benefits of SKI-G-801 administration as part of the chemotherapy regimens demonstrate a common advantage of this inhibitor, in the form of enhanced CD4+ effector memory cells and increased macrophages with a high expression of CD86, in both TC1 and C3PQ tumor models (Figure 6). Here, CD86 is linked to neoplasm.